Dong-A PharmTech’s marketing partner, Valenta Pharmaceuticals, is set to launch Zydena during the fourth quarter of 2008.
According to the company, Zydena (generic name, udenafil) is a new long-acting erectile dysfunction drug that will compete with Viagra and Cialis but is distinguished by its long action and low incidence of unfavorable side effects such as vision disturbances and muscle pain. Zydena is expected to capture a significant share of the erectile dysfunction (ED) market in Russia in coming years.
Dong Hyun Park, president of Dong-A PharmTech, said: “The approval of Zydena in Russia marks a major milestone as we continue to execute our global development and marketing strategy.
“We congratulate Valenta Pharmaceuticals for its diligent efforts in assisting us in obtaining a timely approval in Russia and look forward to working with them to aggressively launch Zydena in Russia’s growing ED market.”